The Effect of Heparin on Inhalation Injury

Sponsor
Tehran University of Medical Sciences (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01454869
Collaborator
(none)
0
1
2
28
0

Study Details

Study Description

Brief Summary

This is a prospective randomized clinical trial about the efficacy of heparin nebulization on lung injury score in inhalation burn injury in Mothary burn hospital. This study would consist of 170 burn patients with documented inhalation injury in 2 arms (control group and study group). Allocation ratio is1:1. Masking was not possible. The patients' primary outcome will be assessed for Lung Injury Scale and the patients' secondary outcome will be assessed for mortality, Coagulation tests (PT, PTT), ICU and hospital stay and duration of mechanical ventilation support. Duration of this study is about 32 months.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

This study would consist of 170 burn patients with documented smoke inhalation injury who will be randomized to receive either standard care alone (control group) or standard care plus heparin nebulization in combination with intravenously administrated fresh frozen plasma (study group). Standard care treatment consist of: chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization (100-200 µgQ4h)/N-acetyl cysteine 20% nebulization (3cc Q4h) and if needed mechanical ventilation support. Study care treatment consist of: Standard care + Heparin nebulized administration(5000U every 4 hours for 7 days) and fresh frozen plasma intravenously administration (10 cc/Kg daily for 7 days) The patients' primary outcome will be assessed for Lung Injury Scale (LIS) every day by using fallowing parameters: (1) chest X-ray evaluated for alveolar consolidation (2) ratio of the partial pressure of oxygen in arterial blood to the inspiratory fraction of oxygen (3) PEEP level if ventilated (4) respiratory compliance if known Parameter Finding Value Rx.Torax no alveolar consolidation 0 alveolar consolidation de 1 quadrant 1 alveolar consolidation de 2 quadrant 2 alveolar consolidation de 3 quadrant 3 alveolar consolidation de 4 quadrant 4 Hypoxemia PaO2/FIO2 > 300 0 PaO2/FIO2 225 - 299 1 PaO2/FIO2 175 - 224 2 PaO2/FIO2 100 - 174 3 PaO2/FIO2 < 100 4 PEEP PEEP <= 5 cm H2O 0 PEEP 6

  • 8 cm H2O 1 PEEP 9 - 11 cm H2O 2 PEEP 12 - 14 cm H2O 3 PEEP >= 15 cm H2O 4 Compliance >= 80 mL/cm H2O 0 compliance 60 - 79 mL/cm H2O 1 compliance 40 - 59 mL/cm H2O 2 compliance 20 - 39 mL/cm H2O 3 compliance <= 19 mL/cm H2O 4 2 The patients' secondary outcome will be assessed for mortality(for 28 days post injury), Coagulation tests(PT,PTT) (for 7 days post injury),ICU and hospital stay(for 7 days post injury) and duration of mechanical ventilation support(for 7 days post injury). In each group 85 Patients will be selected by simple randomization. Allocation ratio is1:1. Blinding of this study was not possible.

PEEP: positive end expiratory pressure- PaO2: partial pressure of oxygen in arterial blood-

FIO2: inspiratory fraction of oxygen PT: prothrombin time- PTT: partial thrombin time- ICU:

intensive care unite- Rx: X-Ray

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Heparin Nebulization on Lung Injury Score in Inhalation Burn Injury
Study Start Date :
Feb 1, 2012
Anticipated Primary Completion Date :
Jun 1, 2012
Anticipated Study Completion Date :
Jun 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard care

nac + salotamul

Drug: standard care
Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
Other Names:
  • routin
  • Experimental: heparin group

    heparin group

    Drug: Heparin
    Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
    Other Names:
  • new
  • Outcome Measures

    Primary Outcome Measures

    1. Lung Injury Score [Daily untill 7 days post injury]

      (1) chest X-ray evaluated for alveolar consolidation (2) ratio of the partial pressure of oxygen in arterial blood to the inspiratory fraction of oxygen (3) PEEP level if ventilated (4) respiratory compliance

    Secondary Outcome Measures

    1. Mortality [28 days post injury]

      Physical exam & EKG

    2. pt/ptt [Up to 7 days post injury]

      Daily

    3. Duration of mechanical ventilation [7 days post injury]

    4. Duration of hospital stay [7 days post injury]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Burn patients admitted to Motahary burn center with documented inhalation injury (as defined by clinical or bronchoscopic evaluation)
    Exclusion Criteria:
    • Non-survivable burn patients;

    • history of coagulation disease;

    • chronic obstructive pulmonary disease(COPD);

    • pneumonia diagnosed at admission;

    • inability to confirm definitive diagnosis of inhalation injury and co poisoning or Cyanide hydrogen intoxication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shahid Mothary Burn Hospital Tehran Iran, Islamic Republic of

    Sponsors and Collaborators

    • Tehran University of Medical Sciences

    Investigators

    • Study Chair: Seyed H Salehi, MD, Burn research of Tehran university of Medical Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Tehran University of Medical Sciences
    ClinicalTrials.gov Identifier:
    NCT01454869
    Other Study ID Numbers:
    • 89-04-129-12415
    First Posted:
    Oct 19, 2011
    Last Update Posted:
    Dec 17, 2012
    Last Verified:
    Dec 1, 2012
    Keywords provided by Tehran University of Medical Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 17, 2012